Why China Pharma Holdings, Inc.’s (CPHI) Stock Is Down 5.37%
As of Friday, August 07, China Pharma Holdings, Inc.’s CPHI share price has dipped by 5.37%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People’s Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection for edema diseases, hypertension, acute renal failure, hyperkalemia, hypercalcemia, and acute drug poisoning; and Candesartan for hypertension. It offers Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and Pseudophedrine Hydrochlorida sustained release tablets, as well as Hepatocyte growth-promoting factors, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. In addition, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection for nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It supplies its products to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistics companies. The company is based in Haikou, the People’s Republic of China.
Commentary & Analysis
Why China Pharma Holdings, Inc.’s (CPHI) Stock Is Down 6.16%
As of Thursday, August 06, China Pharma Holdings, Inc.’s CPHI share price has dipped by 6.16%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why China Pharma Holdings, Inc.’s (CPHI) Stock Is Down 8.46%
As of Friday, July 31, China Pharma Holdings, Inc.’s CPHI share price has dipped by 8.46%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why China Pharma Holdings, Inc.’s (CPHI) Stock Is Down 10.38%
As of Friday, July 31, China Pharma Holdings, Inc.’s CPHI share price has dipped by 10.38%, which has investors questioning if this is right time to buy.Jenna Brashear
Why China Pharma Holdings, Inc.’s (CPHI) Stock Is Down 6.15%
As of Wednesday, July 29, China Pharma Holdings, Inc.’s CPHI share price has dipped by 6.15%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | CPHI | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $32.7 | $609.5 | 13% |
|
| Shares Out (Mil) | 40.5 | 43.4 | 43% |
|
| Institutional Ownership | 0.5% | 83.9% | 1% |
|
| Float (Mil) | 3.3 | 45.7 | 8% |
|
| Beta | 1.07 | 0.73 | 64% |
|
| Avg Daily Volume (000s) | 133 | 309 | 40% |
|
| Price Change (52-week) |
(58.0%) | 64.9% | 13% |
|
| Growth | CPHI | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (17.8%) | 6.7% | 3% |
|
| Net Income (5yr) | (2.0%) | (1.6%) | 37% |
|
| EPS (5yr) | 53.1% | 15.1% | 94 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 51.5% | (15.0%) | 94% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | CPHI | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $4 | $317 | 5% |
|
| Net Income (TTM) (Mil) | ($5) | ($11) | 34% |
|
| EPS (TTM) | ($0.227) | ($0.700) | 33% |
|
| Operating Cash Flow (TTM) (Mil) | $-0 | ($7) | 32% |
|
| Net Cash Flow (TTM) (Mil) | na | $6 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 10% |
|
| Enterprise Value (Q1) (Mil) | $46 | $525 | 15% |
|
| Valuation | CPHI | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.85 | 2.61 | 17% |
|
| P/E | na | 17.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | CPHI | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 11.8% | 68.8% | 11% |
|
| Net Margin | (114.3%) | 0.8% | 7% |
|
| ROA | (15.3%) | (22.7%) | 22% |
|
| ROE | (21.0%) | (22.8%) | 23% |
|
| Liabilities to Assets | 19.1% | 33.1% | 12% |
|
| F-Score | 4 | 3 | 33% |
|
China Pharma Holdings, Inc. did not pass any screens on 9/11/2026.
